InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces their participation in BioTechX Europe 2025 which is to be held from October 6-8, 2025 at Messe Basel, Switzerland.
Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, and Igor Goryanin, Professor at University of Edinburgh, will host a roundtable discussion entitled, "Integrating Artificial Intelligence with Quantitative Systems Pharmacology (QSP): Opportunities and Challenges" on October 6, 10:40 a.m. CET. This discussion will explore how AI can be integrated into QSP workflows. It will highlight key opportunities for AI to enhance QSP models, address challenges related to interpretability, and outline future directions for broader adoption in pharma, biotech, and precision medicine.
In addition to the roundtable discussion, InSysBio is going to present their modeling services for drug research and development in frames of the exhibition.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | June 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Jun 2021 16:46
InSysBio's student to defend diploma thesis
Elena Vasileva, student of Lomonosov Moscow State University (MSU) has developed her diploma thesis in InSysBio and successfully passed its defense. Her diploma thesis entitled “Optimization of anti-CD47 therapeutic agent dosage using PK/PD modeling” was supervised by Oleg Demin Jr, Head of Oncology and Immuno-Oncology at InSysBio.
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
| ||||
Thank you for your message! We will get back to you shortly.
